

1 **Prediction of antidepressant side effects in the Genetic Link to Anxiety and**
2 **Depression Study**

3
4 Danyang Li, PhD 1*, Yuhao Lin, MSc 1, Helena L. Davies, PhD 1,2,3, Johan Källberg
5 Zvrskovec, MSc 1, Rujia Wang, PhD 1, Chérie Armour, PhD 4, Ian R. Jones, PhD 5,
6 Andrew M. McIntosh, MD 6, Nathalie Kingston, PhD 7, John R. Bradley, PhD 7,
7 Christopher Hübel, PhD 1,8, Gursharan Kalsi, PhD 1,9, Jonathan R. I. Coleman, PhD
8 1,9, the NIHR BioResource consortium, Matthew Hotopf, PhD 9,10, Thalia C. Eley,
9 PhD 1, Evangelos Vassos, PhD 1, Raquel Iniesta, PhD 11,12, Gerome Breen, PhD 1*

10
11 1 = Social, Genetic and Developmental Psychiatry Centre, King's College London,
12 London

13 2 = Mental Health Center Ballerup, Copenhagen University Hospital – Mental Health
14 Services CPH, Center for Eating and feeding Disorders Research, Denmark

15 3 = Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde,
16 Institute of Biological Psychiatry, Denmark

17 4 = Research Centre for Stress Trauma and Related Conditions (STARC), School of
18 Psychology, Queen's University Belfast, Belfast

19 5 = National Centre for Mental Health, Cardiff University, Cardiff

20 6 = Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh,
21 Edinburgh

22 7 = University of Cambridge, Cambridge

23 8 = National Centre for Register-based Research, Aarhus University, Aarhus

24 9 = UK National Institute for Health and Social Care Research (NIHR) Biomedical
25 Research Centre for Mental Health, South London and Maudsley Hospital, London

26 10 = Institute of Psychiatry, Psychology and Neuroscience, King's College London,
27 London

28 11 = Department of Biostatistics & Health Informatics, King's College London, London

29 12 = King's Institute for Artificial Intelligence, King's College London, London

30 * = Corresponding authors

31 **Abstract:**

32 Antidepressants are the most common treatment for moderate or severe depression.
33 Side effects are crucial indicators for antidepressants, but their occurrence varies
34 widely among individuals. In this study, we leveraged genetic and medical data from
35 self-reported questionnaires in the Genetic Links to Anxiety and Depression (GLAD)
36 study to build prediction models of side effects and subsequent discontinuation across
37 three antidepressant classes (SSRI, SNRI, tricyclic antidepressant (TCA)) at the first
38 and the last (most recent) year of prescription. We included 259 predictors spanning
39 genetic, clinical, illness, demographic, and antidepressant information. Six prediction
40 models were trained, and their performance was compared. The final dataset
41 comprised 4,354 individuals taking SSRI in the first prescription and 3,414 taking SSRI,
42 SNRI or TCA in the last year of prescription. In the first year, the best area under the
43 receiver operating characteristic curve (AUROC) for predicting SSRI discontinuation
44 and side effects were 0.65 and 0.60. In the last year of SSRI prescription, the highest
45 AUROC reached 0.73 for discontinuation and 0.87 for side effects. Models for
46 predicting discontinuation and side effects of SNRI and TCA showed comparable
47 performance. The history of side effects and discontinuation of antidepressant use
48 were the most influential predictors of the outcomes in the last year of prescription.
49 When examining 30 common antidepressant side effect symptoms, most of them were
50 differentially prevalent between antidepressant classes. Our findings suggested the
51 feasibility of predicting antidepressant side effects using a self-reported questionnaire,
52 particularly for the last prescription. These results could contribute valuable insights
53 for the development of clinical decisions aimed at optimising treatment selection with
54 enhanced tolerability but require replication in medical record linkage or prospective
55 data.

56 Introduction

57 Antidepressants are commonly prescribed medications, but both clinicians and their patients
58 face uncertainty and concerns due to a lack of ability to accurately predict who will
59 experience side effects. The majority of individuals taking antidepressants report
60 experiencing at least one side effect¹. In clinical trials, more than half of individuals
61 discontinue medication within six months of starting treatment, with side effects being the
62 most commonly cited contributing factor². Side effects often result in staged and/or
63 inadequate dosing, which is associated with a lack of remission or delayed remission¹. Some
64 side effects, such as fatigue, sleep change, and cognitive impairment phenomenologically
65 overlap with depression symptoms and related comorbidities, such as anxiety. This overlap
66 further complicates treatment decisions such as dose adjustment or the selection of
67 appropriate initial or alternative medications.


68
69 Tricyclic antidepressants (TCAs) were the dominant medications used to treat depression
70 before the 1990s. Currently, second-generation antidepressants such as selective serotonin
71 reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are
72 first-line treatments for depression. All antidepressants operate by targeting monoamine
73 neurotransmitters to increase activation of postsynaptic receptors³. Individuals taking TCAs
74 are more likely to discontinue treatment, to experience lower tolerability and increased
75 cardiac side effects compared to those taking second-generation antidepressants^{4,5}.
76 Conversely, side effects such as sexual dysfunction, insomnia, nausea, irritability, and
77 anxiety are more prominent response to SSRIs and SNRIs⁶. Nevertheless, clarity over which
78 side effect symptoms are specific to different antidepressants is lacking.

79
80 Within the same type of drugs, there is considerable inter-individual variance in side effect
81 occurrence and severity. Various factors, including sex⁷ and clinical features like depression
82 severity⁸, have been associated with antidepressant tolerability and adherence.
83 Pharmacogenomic testing is an emerging strategy to inform medication selection and dose
84 decisions based on individual genetic variations. Variants such as those found in the
85 cytochrome P450 genes *CYP2C19* and *CYP2D6* are linked to antidepressant metabolism
86 and clearance. They can cause differences in enzyme activity that influence antidepressant
87 response and side effects, although their reported effects are inconsistent among studies^{9,10}.
88 In addition, polygenic scores (PGSs) related to depression have been reported to be
89 predictive of side effects that overlap with depressive symptoms, such as suicidality and
90 anxiety¹¹. The multi-PGS framework allows combined analysis of multiple relevant PGSs
91 associated with a specific trait or outcome, with the aim of improved prediction accuracy
92 compared to a single PGS^{12,13}.

93
94 Side effects could be influenced by a combination of many factors spanning attributions,
95 illness representations, personality, clinical, genetic, and social factors. In contrast with
96 traditional statistical models, machine learning methods can optimally be used for prediction
97 analyses involving large datasets that show complex interrelationships and are very often
98 high-dimensional. Machine learning can effectively capture both linear and non-linear
99 relationships across multiple data sources^{14,15}. These methods employ data-resampling
100 procedures in holdout samples to estimate models' parameters and to internally validate

101 inter-variable relationships in unseen individuals. To achieve generalisation, models are
 102 validated in independent samples not used for model building. Published machine learning
 103 models have used demographics, diagnoses, laboratory values and medication information
 104 across various drugs to predict side effects in clinical trials and electronic health record
 105 data¹⁶. For antidepressants, treatment response and improvement in depression severity
 106 have been mostly studied within groups of individuals receiving the same treatment¹⁷.
 107 However, few studies have investigated side effect prediction combining genetic and clinical
 108 measures¹⁸.

109
 110 In this study, we leveraged self-reported questionnaires and genome-wide genetic data from
 111 the Genetic Links to Anxiety and Depression Study (GLAD)¹⁹ to build prediction models of
 112 side effect occurrence for three common antidepressant classes: SSRIs, SNRIs, and TCAs.
 113 Self-reported side effects and discontinuation (due to side effects) were obtained from the
 114 first and last (most recent) year of prescription. We applied six machine learning models
 115 incorporating 259 predictors covering five categories: genetic variables, clinical measures,
 116 demographic characteristics, illness information, and antidepressant history (Figure 1). We
 117 also presented the prevalence, correlation, and association with antidepressant classes in
 118 30 common side effect symptoms. By integrating data on multiple antidepressants in a large
 119 cohort, we aimed to provide a more realistic portrayal of real-world drug prescriptions and
 120 enhance the potential for early and accurate detection of side effects in personalised
 121 antidepressant prescriptions.



122
 123 Figure 1. Side effect outcome and prediction models
 124

125 **Methods**

126 **Study population**

127 All participants in this study were from the Genetic Links to Anxiety and Depression (GLAD)
128 Study. In summary, individuals from the general population in the UK were recruited using
129 a combination of traditional and social media, as well as clinic-based recruitment, based on
130 the eligibility criterion of meeting a DSM-5 diagnosis for major depressive disorder (MDD)
131 or any anxiety disorder. Participants were invited to complete online sign-up questionnaires,
132 covering demographics, illness, and psychological and behavioural phenotypes relevant to
133 anxiety and depression. Subsequently, participants filled out additional questionnaires that
134 more deeply detailed medication use, psychiatric disorders beyond depression and anxiety,
135 lifestyle, and personal history. A more comprehensive description can be found in Davies et
136 al¹⁹. GLAD received ethical approval from the London - Fulham Research Ethics Committee
137 (REC reference: 18/LO/1218), while the NIHR BioResource obtained approval from the East
138 of England - Cambridge Central Committee (REC reference: 17/EE/0025).

139

140 **Polygenic score (PGS)**

141 Detailed genotyping and imputation steps can be found in [Supplementary Methods](#). Imputed
142 genotypes were aligned with the Hapmap3 reference panel to remove strand-ambiguous
143 SNPs and for PGS calculation. PGSs were computed using MegaPRS²⁰ via the GenoPred
144 pipeline²¹. PGSs were reference standardised: MegaPRS was used to first construct PGS
145 in the 1000 Genome European reference panel, following which the mean and standard
146 deviation of PGS output in GLAD samples were scaled to the mean and standard deviation
147 of the reference. GWAS summary statistics from 102 traits were incorporated for both
148 reference PGSs and GLAD PGSs in this study ([Supplementary Table 1](#)). PGSs from the
149 GLAD were further rescaled using the reference PGSs to ensure a comparable distribution
150 with the reference.

151

152 **Inferred cytochrome metabolic phenotypes**

153 We selected CYP2C19 and CYP2D6 to examine their pharmacogenetic effects, as
154 suggested by the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline
155 for SSRIs and Tricyclic antidepressants^{22,23}. Phasing was conducted using SHAPEIT4
156 software for the regions of CYP2C19 and CYP2D6 obtained from PharmGKB
157 (<https://www.pharmgkb.org/>)²⁴. Star alleles were identified by SNPs matched between the
158 phased data and CPIC definitions (<https://cpicpgx.org/>; downloaded June 2022)²⁵. Allele
159 function and activity values were annotated to include alleles with no, decreased, normal,
160 and increased function (<https://cpicpgx.org/>)²². Metabolic phenotypes of CYP2C19,
161 including poor, intermediate, normal, rapid/ultrarapid, were inferred from genotypes, and
162 classified based on CPIC guidelines. CYP2D6 phenotypes (poor, intermediate, normal)
163 were defined by the consensus recommendations of CPIC and the Dutch Pharmacogenetics
164 Working Group (DPWG)²⁶. Since structural variants of CYP2D6 were unavailable in the
165 imputed genotype data, no rapid/ultrarapid metabolisers were identified. The activity score
166 was determined by summing the activity values of the two star alleles in each individual.

167

168 **Outcomes**

169 Participants provided self-reported side effect data for commonly prescribed
170 antidepressants in the UK, including eight selective serotonin reuptake inhibitors (SSRIs), 2
171 serotonin and norepinephrine reuptake inhibitors (SNRIs), and 10 tricyclic antidepressants

172 (TCAs) ([Supplementary Table 2](#)). Participants were asked about any experienced side
173 effects from the prescribed antidepressants and then selected one or more side effects from
174 a list of 30 common symptoms, including *dry mouth, sweating, nausea, vomiting, diarrhoea,*
175 *constipation, headache, dizziness, memory problems, attention/concentration difficulties,*
176 *shaking, muscle pain, sleepiness/drowsiness, difficulty getting to sleep, increased anxiety,*
177 *fast heartbeat, restlessness/agitation, fatigue or weakness, changes in appetite, weight gain,*
178 *weight loss, itching, rash, runny nose, reduced sexual desire/function, menstrual*
179 *problems/irregularities, blurred vision, suicidal thoughts, attempted suicide, and others.*
180 Discontinuation was indicated by the response to whether the participant had to stop taking
181 the antidepressant due to side effects.

182
183 Antidepressants were ordered by the age at which they were prescribed for each participant.
184 In this study, we included antidepressants prescribed in the first and the most recent (last)
185 year. Information on side effects and discontinuation due to side effects were collected for
186 each antidepressant of each individual. To minimise self-report errors, we limited
187 participants to those who reported at most three different antidepressants during both the
188 first and the last year. Specifically, for first year antidepressants, we focused on whether
189 each participant experienced any side effects or discontinuation with SSRI drugs. For last
190 year antidepressants, we considered the occurrence of side effects and discontinuation for
191 SSRI, SNRI, and TCA antidepressants. In cases where participants were prescribed more
192 than one antidepressant within the same class in either year, side effects and
193 discontinuation were counted if they occurred with either one of the drugs.

194 195 **Predictors**

196 We curated 259 items across five categories, including demographics, illness, clinical
197 evaluation, antidepressant history, and genetics, to serve as predictor variables. Core
198 demographic details (e.g., sex, employment status, years of education, marital status, BMI)
199 and health conditions (neurological, allergic, cardiovascular, respiratory, digestive,
200 inflammatory, cancer-related) were obtained from the sign-up questionnaire. Clinical and
201 psychiatric symptoms were assessed through various measures, including lifetime
202 measures of MDD and anxiety (adapted from the Composite International Diagnostic
203 Interview - Short Form (CIDI-SF)), Standardised Assessment of the Severity of Personality
204 Disorders (SASPD), and lifetime assessment of panic disorder (adapted from DSM-5/ICD-
205 11 checklists). In terms of antidepressant histories, we considered antidepressant initiation
206 and last prescription age, the total number and duration of antidepressants taken, and the
207 average number of side effect occurrence, discontinuation, and efficacy (effectiveness of
208 each antidepressant) calculated from all antidepressants taken before the last year. Genetic
209 factors included PGSs for 102 traits and cytochrome metabolic phenotypes, as described
210 above. The complete list of predictors was provided in [Supplementary Table 3](#).

211 To ensure all predictors in the model have been characterised before the outcome,
212 we chose predictors that preceded the antidepressant initiation including all genetic
213 variables, sex, ethnicity, antidepressant initiation age, lifetime depression and anxiety
214 symptoms to predict outcomes of antidepressants taken in the first year. All predictors were
215 added to the model for the prediction of antidepressants taken in the last year.

216

217 **Prediction modelling**

218 **– Data processing**

219 We removed predictors with missing values > 30%. The remaining were imputed using the
220 random forest algorithm in the MICE package²⁷. Predictors with either zero variance or a
221 correlation higher than 0.8 with another predictor were excluded. For categorical factors with
222 more than two categories, they were converted into a set of binary dummy variables in the
223 elastic net and SVM models. Normalisation was applied to each predictor to achieve a
224 standard deviation of one and a mean of zero before training the SVM.

225

226 **-- Model building**

227 We applied six prediction models, including elastic net, support vector machine (SVM) with
228 radial basis function (RBF) and polynomial kernels, XGBoost, random forest, and cubist in
229 this study. A stratified split was employed based on the outcome, randomly allocating 80%
230 for the training data and the remaining 20% for the testing data, maintaining the same
231 outcome proportions as in the original population in each split. Within the training data, a 5-
232 fold stratified cross-validation with 5 repeats were conducted, assigning 20% of the data as
233 a validation set for hyperparameter prioritisation and the remainder for model training. The
234 receiver operating characteristic area under the curve (AUROC) was assessed in the
235 validation set to identify models that maximise performance. The best performing models,
236 along with their hyperparameter combinations, were extracted and employed to predict the
237 outcome class in the test data. Beyond AUROC, we reported accuracy and precision-recall
238 area under the curve (AUPRC) of test data for each model. After model training, a logistic
239 regression was fitted between the probability estimates and the true probabilities to produce
240 the calibrated estimates. More description of each model and data processing can be found
241 in [Supplementary Methods](#).

242

243 **-- Feature importance**

244 For every predictor category (genetics, demographics, illness, clinical and antidepressant
245 information) in the outcomes of drug prescriptions during the last year, we evaluated their
246 importance by excluding the corresponding category of predictors and retrained the model
247 using the same strategy for model building and estimation as described above. The relative
248 reduction in AUROC was calculated for each predictor category compared to the models
249 with the complete set of predictors.

250

251 **-- Prediction across antidepressant classes**

252 For each antidepressant class in the last year of prescription, we compared the model
253 performance between the same drug (training and testing data within the same drug class)
254 and cross drug (training and testing data across different drug classes) analyses to
255 determine the specificity of the model to the drug class. The models with the best
256 performance, identified through the same drug analysis, were then tested on data from other
257 drugs. The Kruskal-Wallis test was used to examine the differences in AUROC values
258 obtained from the same antidepressant class and cross-class analyses.

259

260 **Association of side effects with predictors at the last prescription**

261 To further make each predictor's effect more interpretable and understandable, a univariate
262 logistic regression was performed between each predictor and the six outcomes at the last
263 prescription to evaluate their associations. The false discovery rate was used to adjust the
264 statistical significance for each outcome.

265 266 **Correlation of side effect symptoms and drug effect difference**

267 Tetrachoric correlations were applied to assess the correlation of side effect symptoms
268 among SSRIs, SNRIs, and TCAs. Each side effect symptom was coded as a binary variable,
269 with 1 indicating the occurrence of the symptom with any prescribed drugs and 0 showing
270 the absence of the symptom. Hierarchical clustering analysis measured by Euclidean
271 distance was conducted on the distance matrix derived from the correlation matrix of the
272 symptoms. A generalised linear mixed model was constructed to investigate the impact of
273 drug class on each side effect symptom, with drug class as a fixed variable and individual
274 ID as a random variable. SSRIs were set as the reference for comparison with SNRIs and
275 TCAs. Statistical significance was adjusted using the Bonferroni test across the 30
276 symptoms.

277
278 All prediction modelling and association analyses were performed using R v4.2.3²⁸.


279 280 **Results**

281 **Participant characteristics**

282 All participants in this study were part of the Genetic Links to Anxiety and Depression (GLAD)
283 Study. Overall, 8219 individuals completed the antidepressant questionnaire, and 5358 had
284 available genetic data. In the first year of prescription, most individuals were prescribed
285 SSRIs, with 45% continuing SSRIs and 19.0% transitioning to other antidepressants in the
286 second prescription year ([Supplementary Figure 1](#)).

287
288 The average prevalence of side effects and discontinuation during the initial five prescription
289 years was 74% and 29%, respectively ([Figure 2](#)). In the first year, 6% of participants who
290 initially experienced side effects reported none in the second year. Conversely, 20% of
291 participants without side effects in the first year experienced at least one side effect symptom
292 in the second year ([Supplementary Table 4](#)). For the discontinuation outcome, 33% of
293 participants transitioned from discontinuation to no discontinuation in the first two years of
294 prescription. Approximately 8% of participants experienced discontinuation in the second
295 prescription year after having no discontinuation in the first year ([Supplementary Table 4](#)).

296
297 For the prediction models, we included 4354 individuals for SSRIs in the first year of
298 prescription. In addition, 3414 had data for an antidepressant prescription in the last year,
299 comprising 60% (2036) on SSRIs, 22% (753) on SNRIs, and 29% (982) on TCAs. In the
300 initial year, 73% of participants taking SSRIs experienced side effects, and 32% reported
301 discontinuation. In the last year, the reported side effects prevalence for SSRIs was 75%,
302 lower than SNRIs (84%) and TCAs (76%). Discontinuation was highest for TCAs (37%),
303 followed by SSRIs (20.7%) and SNRIs (20.6%) ([Table 1](#)).



304
305
306
307
308
309

Figure 2. Side effects and discontinuation occurrence at the first five years of prescription, where the x-axis represented each individual (ordered by yes first), and the y-axis showed the time of prescription.


Table 1. Side effects and discontinuation at the prescription of the first and last year

| | Discontinuation | Side effect symptoms |
|---|-----------------|----------------------|
| Prescription at the first year (N (yes%)) | | |
| SSRI | 3947 (31.6) | 4286 (73.3) |
| Prescription at the last year (N (yes%)) | | |
| SSRI | 1770 (20.7) | 1986 (75.3) |
| SNRI | 640 (20.6) | 733 (83.5) |
| TCA | 834 (37.2) | 959 (76.4) |

310
311
312
313
314
315
316
317
318
319
320
321

Prediction of antidepressant side effects and discontinuation

In the initial year of SSRIs prescription, the best AUROCs for predicting discontinuation and side effects were 0.65 and 0.60, respectively, achieved by XGBoost (Figure 3a). In the last year of SSRIs prescription, the highest AUROC observed for discontinuation was 0.73, and 0.87 for side effects (Figure 3a). Models including elastic net, random forest and XGBoost achieved AUROC values around 0.70 for discontinuation and above 0.85 for side effects. For SNRIs, the best AUROC was observed in random forest, with 0.71 for discontinuation and 0.80 for side effects. The best models for TCAs had AUROC of 0.71 and 0.87 for predicting discontinuation and side effects, respectively (Supplementary Figure 2). More detailed results for AUROC, AUPRC and accuracy were provided in Supplementary Table 5.



328 Figure 3. ROC curve (a) and feature importance (b) of SSRIs discontinuation and side effects.
 329 Antidepressant history included information of antidepressant initiation and last prescription age,
 330 total number and duration of prescribed antidepressants, and the average number of efficacy ratings,
 331 side effect occurrence, and discontinuation of all antidepressants taken before the last year of
 332 prescription.

333

334 For the last year of prescription, we performed cross-class analysis to assess model
 335 specificity, comparing the performance of the same training data when tested on different
 336 antidepressant classes. For both discontinuation and side effects, the Kruskal-Wallis test
 337 revealed no statistically significant differences between the same antidepressant class and
 338 different classes for any drug-derived models. This suggested that these models were
 339 nonspecific to antidepressant class in the last year of prescription (Supplementary Figure 3).

340

341 Feature importance at the prescription of last year

342 Next, for each drug class in the last prescription, we evaluated the importance of each
 343 predictor category by removing corresponding categories one at a time and retrained the
 344 model selected by the best performance of AUROC. We chose XGBoost in this step given
 345 it showed superior performance on average across all outcomes described above. Overall,
 346 antidepressant history emerged as the most influential category in predicting discontinuation
 347 and side effects during the last year of prescription, with a relative reduction in AUROC
 348 ranging from 11.4% to 24.0% for discontinuation and 20.4% to 37.1% for side effects (Figure
 349 3b, Supplementary Figure 4). Other clinical measures made a modest contribution to the
 350 model for discontinuation, with an impact of 10.0% in SSRIs, 1.4% in SNRIs, and 3.0% in
 351 TCAs. Their impact on side effects was considerably less, with the highest relative AUROC
 352 reduction of 1.0% in TCA drugs. Genetic factors exhibited the highest impact (1.1%) in
 353 predicting side effects and 0.3% for discontinuation (Supplementary Figure 4).


354

355 Association at the prescription of last year

356 We also conducted univariate logistic regression to examine the association of side effects
357 and discontinuation outcomes with individual features during the last year of prescription.
358 As expected, we observed a strong association between side effect/ discontinuation history
359 and both outcomes across all antidepressant classes ([Supplementary Figure 6](#)). For the
360 discontinuation outcome, clinical measures related to depression (low mood, number of
361 episodes, thoughts about death, group/talking therapy), anxiety (anxiety symptoms, duration
362 of worry), and panic disorder (choking, strong fears of attack situations, panic symptoms,
363 medical conditions) were linked to SSRIs, while no significance was observed in other drugs.
364 For side effects, antidepressant prescription age and panic disorders (including panic
365 symptoms, feeling hot or cold) showed associations across all drugs. Other features,
366 including marital status, educational attainment, depressive symptoms, and panic symptoms
367 (strong fears of attack situations, fear of losing control or going crazy, sweating) were
368 associated with any two of the three antidepressant classes ([Supplementary Figure 6](#)).
369

370 **Side effect symptoms correlation and drug specificity**

371 To investigate the correlations among side effect symptoms and identify how they differed
372 across drug classes, we collected 30 common symptoms from the self-reported
373 questionnaire. In [Figure 4](#), we present the prevalence of side effect symptoms for each drug
374 class across all prescriptions. The most reported side effects included reduced sexual desire,
375 dry mouth, sleepiness/drowsiness, and weight gain, while rash, runny nose, menstrual
376 irregularities, and weight loss had the lowest prevalence. TCAs had most individuals
377 reporting sleepiness/drowsiness, weight gain, dry mouth, and changes in appetite. Reduced
378 sexual desire, nausea, dry mouth, and concentration difficulties were the most common
379 symptoms of SSRIs. Reduced sexual desire, sweating, dry mouth, and nausea were
380 predominantly reported in SNRIs ([Supplementary Table 6](#)).
381



382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400


401

Figure 4. Prevalence of side effect symptoms in antidepressant classes. Symptoms were ordered by their prevalence in the studied population.

For individuals who reported more than one side effect symptom, we examined the correlations between these symptoms across medications. Significant correlations were evident between certain symptoms, such as nausea and vomiting ($r = 0.797$), memory problems and concentration difficulties ($r = 0.803$), itching and rash ($r = 0.782$), as well as suicidal thoughts and attempted suicide ($r = 0.861$). Moderate correlations were observed between sleepiness/drowsiness and fatigue or weakness ($r = 0.663$), headache and dizziness ($r = 0.653$), and a symptom cluster comprising increased anxiety, restlessness/agitation, and fast heart beat (increased anxiety vs restlessness/agitation: $r = 0.743$; fast heart beat vs restlessness/agitation: $r = 0.689$; fast heart beat vs increased anxiety: $r = 0.639$, [Supplementary Figure 6](#)).

Finally, we used generalised linear mixed models to investigate the impact of antidepressant classes on each side effect symptom. Compared to SSRIs, SNRIs and TCAs were associated with fewer reports of symptoms like suicidal thoughts, attempted suicide, increased anxiety, diarrhoea, weight loss, vomiting, restlessness/agitation, reduced sexual desire, rash, headache, and difficulty getting to sleep. Conversely, constipation showed a

402 higher occurrence in both SNRIs and TCAs compared to SSRIs. Symptoms such as weight
 403 gain, sleepiness/drowsiness, fatigue or weakness, and changes in appetite were more likely
 404 to occur in TCAs than SSRIs but were comparable between SNRIs and SSRIs. Dry mouth
 405 and concentration difficulties showed no significant differences across all drugs (Figure 5,
 406 [Supplementary Table 7](#)).
 407



408
 409 Figure 5. Association of side effect symptoms with drug classes using SSRIs as reference. Each bar
 410 represents the effect of SNRIs/TCAs on side effect symptoms compared to SSRIs with 95%
 411 confidence intervals.
 412

413 **Discussion**

414 In this study, we find evidence that self-reported side effects and discontinuation (due to
 415 side effects) can be predicted using questionnaires and genetic information, particularly for
 416 the most recent antidepressant treatments. Among all predictors, antidepressant history
 417 including side effects and discontinuation history showed the primary contribution, indicating
 418 individuals tend to have consistent side effect occurrence across different prescriptions.
 419 When examining 30 common antidepressant side effect symptoms, the most prevalent
 420 symptoms were lower sexual desire, dry mouth, and sleepiness/drowsiness. Most of the 30
 421 symptoms were differentially prevalent between antidepressant classes.
 422

423 Using machine learning, our results confirmed predicting side effect occurrence was more
424 accurate for the last antidepressant prescription compared to the initial treatment,
425 particularly when considering antidepressant history. Relatively few studies have
426 investigated how drug history influences adverse reactions to the current treatment.
427 However, similar findings are reported in the available literature. For example, the risk of
428 gastrointestinal side effects in nonsteroidal anti-inflammatory drugs (NSAIDs) could be
429 increased if previous NSAID intolerance was identified²⁹. In hospitalised older patients, a
430 history of experiencing harmful outcomes from medications in the preceding year was shown
431 to predict adverse drug effects from current medications³⁰. A study on treatment-resistant
432 depression also found that a history of electroconvulsive therapy and unsuccessful
433 antidepressant trials were associated with the outcome of vagus nerve stimulation³¹. Despite
434 this, medication history of side effects and discontinuation has been largely overlooked in
435 prediction studies.

436
437 Antidepressant side effects have been linked to the severity of depression, polypharmacy,
438 and comorbid status^{8,32,33}. Similarly, we observed that clinical measures such as a higher
439 score of depression/panic symptoms and number of episodes could increase the risk of side
440 effects and discontinuation, but their effects were less pronounced than the impact of side
441 effects or discontinuation history. We also identified a large correlation of side effect history
442 among antidepressant classes above 0.62 (SSRIs vs SNRIs: $r = 0.66$, SSRIs vs TCAs: $r =$
443 0.68 , SNRIs vs TCAs: $r = 0.62$), suggesting the occurrence of self-reported side effects might
444 be underlined by other factors regardless of antidepressant class, such as pharmacological,
445 or genetic factors, as indicated in other studies¹¹. The role of other factors such as
446 expectation bias should also be considered, especially when using self-reported data³³.

447
448 Genetic predictors, including pharmacokinetic features (*CYP2C19* and *CYP2D6* metabolic
449 phenotypes) along with polygenic risk for multiple disorders and traits only marginally
450 improved model performance in the last prescription. This finding aligned with Poweleit et
451 al.¹⁸, where the predictive ability of *CYP2C19* phenotypes was limited compared to
452 pharmacokinetic parameters including clearance, half-life for escitalopram and sertraline
453 side effects. *CYP2C19* poor metabolisers exhibited an OR of 1.99 for the occurrence of the
454 last SSRI side effect in our univariate association analysis, showing a comparable effect
455 size to other studies^{10,34}. However, statistical significance was not achieved due to limited
456 power. We did not find an association between *CYP2D6* metabolic status and any side effect
457 outcomes and it is important to note that the genotype-determined metabolic phenotype in
458 our study has a lower ability to identify star alleles, particularly for *CYP2D6*. Approximately
459 7% of *CYP2D6* variants are structural variants, so the star allele calls and metabolic
460 phenotype imputation would be influenced by these missing variants in the genotype leading
461 to the misclassification of metabolic phenotypes and higher false negative findings^{25,35}.

462
463 We observed a modest predictive ability of PGSs for side effects and discontinuation.
464 Previous studies have reported PGSs for depression, schizophrenia, attention-deficit
465 hyperactivity disorder, and bipolar disorder with treatment response or resistance, but these
466 results mostly yielded no strong evidence of significant associations^{36,37}. A study showed
467 PGSs were associated with corresponding side effect symptoms, such as the PGS for

468 depression was linked to depressive symptoms including suicidality and anxiety, and the
469 BMI PGS was associated with weight gain side effects¹¹. However, the explained variance
470 attributed to these PGSs (approximately 1%) to predict side effect outcomes was low.
471 Although our study integrated multiple PGS traits to enhance prediction power¹², we lacked
472 PGSs directly related to antidepressant side effects or responses, which need to be the
473 subject of larger studies³⁷. We also acknowledge the need for a larger sample size to fully
474 reflect their predictive ability³⁸. Genetic contribution to antidepressant side effects would be
475 further improved with more precise measures of pharmacogenomic phenotypes and
476 sufficient sample size to maximise the PGS evaluation.

477

478 As mentioned above, the most commonly reported side effects included reduced sexual
479 desire, dry mouth, sleepiness/drowsiness, and weight gain – consistent with findings from
480 other studies^{1,32}. Some symptoms, such as dry mouth, were common in all antidepressant
481 classes, while others, such as reduced sexual desire, were mostly associated with SSRIs
482 or SNRIs, and drowsiness was most prevalent in TCAs. Previous studies have indicated
483 SSRIs were associated with gastrointestinal symptoms, anxiety, insomnia, and sexual side
484 effects, and TCAs broadly conferred an increased risk of weight gain, sedation, sexual
485 dysfunction, and anticholinergic symptoms^{4,6,32,39,40}. We confirmed SSRIs were more likely
486 to cause gastrointestinal symptoms (vomiting, diarrhoea, nausea), restlessness agitation,
487 anxiety, weight loss, reduced sexual desire, and difficulty getting to sleep, while individuals
488 taking TCAs experienced more weight gain, sleepiness/drowsiness, change in appetite, and
489 fatigue or weakness. Anticholinergic symptoms such as constipation were more common
490 with TCAs than SSRIs while dry mouth and concentration difficulties showed no differences
491 among drug classes.

492

493 We found suicidality (attempted suicide and suicidal thoughts) was mostly reported in SSRIs
494 compared to SNRIs or TCAs. The FDA has added a black box warning for increased
495 suicidality risk among adolescents aged 18-24 with SSRIs prescription^{4,41}. However, the
496 effectiveness of this warning is disputed, given increased suicidality among those with
497 severe depression who were not prescribed antidepressants as a result of the warning⁴².
498 While SSRIs were found to increase the risk of suicidality when prescribed for adolescents,
499 the risk was reduced in adults⁴⁰. Among people aged 20 or older when prescribed
500 antidepressants, there was no significant difference in rates of attempted suicide and self-
501 harm between SSRIs and TCAs^{43,44}. When stratifying by age, we found that the difference
502 in the rate of attempted suicide between SSRIs and TCAs was more pronounced in
503 individuals younger than 25 than in older participants ([Supplementary Table 8](#)). Given the
504 retrospective reporting of prescriptions and side effects in our study of a relatively severe
505 study sample, individuals who had suicidal behaviour after taking antidepressants may have
506 failed to respond leading to a potential ‘survivorship bias’ of our samples. Thus, our results
507 should be interpreted with caution with more evidence needed from other studies.

508

509 Our study provides a unique resource to explore the contribution of genetic and medical
510 factors on antidepressant side effects using one of the most powerful and comprehensive
511 self-report records available. Nonetheless, some limitations should be considered. In
512 addition to incomplete metabolic phenotype imputation and limited polygenic prediction due

513 to available PGSs and sample size mentioned above, the retrospective study design with
514 self-report phenotype is prone to subjective interpretations and recall bias. In the GENDEP
515 clinical trial, antidepressant side effects were shown to be reliably measured with self-report
516 instruments, via good agreement with psychiatrists' ratings. However, this evaluation was
517 limited to the trial period³². Linking our data to electronic medical records would allow us to
518 track individuals' antidepressant trajectories through their lifetime with a more precise
519 assessment compared to self-report⁴⁵. Illness perceptions related to antidepressant
520 medication are not available in our data which may be predictive of treatment adherence or
521 continuation⁴⁶. In addition, our data recorded by age did not distinguish whether
522 antidepressants were prescribed simultaneously or not within the same year. Non-
523 antidepressant medication data was unavailable limiting the evaluation of polypharmacy
524 effects. We also did not collect detailed information on antidepressant dosage, atypical
525 antidepressants (such as Bupropion, Trazodone), or rarer side effects such as myocardial
526 infarction. Finally, our study lacks external validation of models in an independent sample.
527 As our results are primarily based on individuals of European ancestry, further analyses are
528 necessary when generalising our findings to other populations with distinct genetic and
529 social backgrounds.

530
531 In conclusion, our study highlighted that self-reported antidepressant side effects and
532 discontinuation can be predicted by incorporating genetic and medical phenotype
533 information, with antidepressant history being a crucial feature. While genetic predictors
534 showed a minor impact, larger samples for discovery GWAS of antidepressant phenotypes
535 and advancements in genetics such as long-read sequencing are needed to fully capture
536 their predictive ability. In our analysis, individuals report experiencing different side effect
537 symptoms across antidepressant classes. Further studies with detailed information on
538 antidepressant regimens and combined treatments will enable a full assessment of
539 antidepressant trajectories and the identification of genetic and clinical risk stratification for
540 potential individualised clinical applications.

541

542 **Data and code availability**

543 The GLAD study data are available via a data request application to the NIHR BioResource
544 ([https://bioresource.nihr.ac.uk/using-our-bioresource/academic-and-clinical-
545 researchers/apply-for-bioresource-data/](https://bioresource.nihr.ac.uk/using-our-bioresource/academic-and-clinical-researchers/apply-for-bioresource-data/)).

546

547 **Funding**

548 This work was supported by the National Institute for Health and Care Research (NIHR)
549 BioResource [RG94028, RG85445], NIHR Biomedical Research Centre [IS-BRC-1215-
550 20018], HSC R&D Division, Public Health Agency [COM/5516/18], MRC Mental Health Data
551 Pathfinder Award (MC_PC_17,217), and the National Centre for Mental Health funding
552 through Health and Care Research Wales. Dr Hübel acknowledges funding from
553 Lundbeckfonden (R276-2018-4581). Johan Källberg Zvrskovec acknowledges funding from
554 the National Institute for Health and Care Research (NIHR) Biomedical Research Centre
555 and Guy's and St Thomas' NHS Foundation Trust. Prof McIntosh received funding from the
556 Wellcome Trust (226770/Z/22/Z).

557

558 **Conflict of interest**

559 Prof Breen has received honoraria, research or conference grants and consulting fees from
560 Illumina, Otsuka, and COMPASS Pathfinder Ltd. Prof Hotopf is the principal investigator of
561 the RADAR-CNS consortium, an IMI public private partnership, and as such receives
562 research funding from Janssen, UCB, Biogen, Lundbeck and MSD. Prof McIntosh has
563 received research support from Eli Lilly, Janssen, and the Sackler Foundation, and has also
564 received speaker fees from Illumina and Janssen.

566 **Acknowledgements**

567 We thank the GLAD Study and NIHR BioResource volunteers for their participation and
568 gratefully acknowledge the NIHR BioResource centres, NHS Trusts, and staff for their
569 contribution. We thank the National Institute for Health Research, and Health Data Research
570 UK as part of the Digital Innovation Hub Programme. This study presents independent
571 research funded by the NIHR Biomedical Research Centre at South London Maudsley NHS
572 Foundation Trust and King's College London. Further information can be found at
573 <http://brc.slam.nhs.uk/about/core-facilities/bioresource>. The views expressed are those of
574 the authors and not necessarily those of the NHS, the NIHR, the HSC R&D Division, King's
575 College London, or the Department of Health and Social Care.


577 **References**

- 578 1. Kelly, K., Posternak, M. & Jonathan, E. A. Toward achieving optimal response: understanding
579 and managing antidepressant side effects. *Dialogues in Clinical Neuroscience* **10**, 409–418
580 (2008).
- 581 2. Sansone, R. A. & Sansone, L. A. Antidepressant Adherence: Are Patients Taking Their
582 Medications? *Innovations in Clinical Neuroscience* **9**, 41–46 (2012).
- 583 3. Hillhouse, T. M. & Porter, J. H. A brief history of the development of antidepressant drugs:
584 From monoamines to glutamate. *Experimental and Clinical Psychopharmacology* **23**, 1–21
585 (2015).
- 586 4. Wang, S.-M. *et al.* Addressing the Side Effects of Contemporary Antidepressant Drugs: A
587 Comprehensive Review. *Chonnam Med J* **54**, 101 (2018).
- 588 5. Hotopf, M., Hardy, R. & Lewis, G. Discontinuation rates of SSRIs and tricyclic antidepressants:
589 a meta-analysis and investigation of heterogeneity. *Br J Psychiatry* **170**, 120–127 (1997).
- 590 6. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: Conceptual
591 foundations and neuronal substrates, drug discovery and therapeutic application.
592 *Pharmacology & Therapeutics* **110**, 135–370 (2006).
- 593 7. Kornstein, S. G. *et al.* Gender Differences in Treatment Response to Sertraline Versus
594 Imipramine in Chronic Depression. *AJP* **157**, 1445–1452 (2000).
- 595 8. De Las Cuevas, C., Peñate, W. & Sanz, E. J. Risk factors for non-adherence to antidepressant
596 treatment in patients with mood disorders. *Eur J Clin Pharmacol* **70**, 89–98 (2014).
- 597 9. Maggo, S. *et al.* Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety,
598 and Neuroticism Are Not Associated With Self-Reported Antidepressant Side Effects. *Frontiers*
599 *in Genetics* **10**, 1199 (2019).
- 600 10. Fabbri, C. *et al.* Effect of cytochrome CYP2C19 metabolizing activity on antidepressant
601 response and side effects: Meta-analysis of data from genome-wide association studies.
602 *European Neuropsychopharmacology* **28**, 945–954 (2018).
- 603 11. Campos, A. I. *et al.* Understanding genetic risk factors for common side effects of
604 antidepressant medications. *Commun Med* **1**, 45 (2021).
- 605 12. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937 polygenic
606 scores. *Nat Commun* **14**, 4702 (2023).
- 607 13. Krapohl, E. *et al.* Multi-polygenic score approach to trait prediction. *Mol Psychiatry* **23**, 1368–
608 1374 (2018).


- 609 14. Bzdok, D., Varoquaux, G. & Steyerberg, E. W. Prediction, Not Association, Paves the Road to
610 Precision Medicine. *JAMA Psychiatry* **78**, 127 (2021).
- 611 15. Bzdok, D., Altman, N. & Krzywinski, M. Points of Significance: Statistics versus machine
612 learning. *Nature Methods* **15**, 233–234 (2018).
- 613 16. Denck, J., Ozkirimli, E. & Wang, K. Machine-learning-based adverse drug event prediction
614 from observational health data: A review. *Drug Discovery Today* **28**, 103715 (2023).
- 615 17. Sajjadian, M. *et al.* Machine learning in the prediction of depression treatment outcomes: a
616 systematic review and meta-analysis. *Psychol. Med.* **51**, 2742–2751 (2021).
- 617 18. Poweleit, E. A. *et al.* Machine Learning-Based Prediction of Escitalopram and Sertraline Side
618 Effects with Pharmacokinetic Data in Children and Adolescents. *Clin Pharma and Therapeutics*
619 *cpt.3184* (2024) doi:10.1002/cpt.3184.
- 620 19. Davies, M. R. *et al.* The Genetic Links to Anxiety and Depression (GLAD) Study: Online
621 recruitment into the largest recontactable study of depression and anxiety. *Behaviour*
622 *Research and Therapy* **123**, 103503 (2019).
- 623 20. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of complex
624 traits from individual-level data or summary statistics. *Nat Commun* **12**, 4192 (2021).
- 625 21. GenoPred at github. <https://github.com/opain/GenoPred>.
- 626 22. Bousman, C. A. *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline
627 for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake
628 Inhibitor Antidepressants. *Clin Pharma and Therapeutics* **114**, 51–68 (2023).
- 629 23. Hicks, J. K. *et al.* Clinical pharmacogenetics implementation consortium guideline (CPIC) for
630 CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
631 *Clinical Pharmacology & Therapeutics* **102**, 37–44 (2017).
- 632 24. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate,
633 scalable and integrative haplotype estimation. *Nat Commun* **10**, 5436 (2019).
- 634 25. Li, D. *et al.* Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant
635 response from 13 clinical studies using genotype imputation. Preprint at
636 <https://doi.org/10.1101/2023.06.26.23291890> (2023).
- 637 26. Caudle, K. E. *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus
638 Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch
639 Pharmacogenetics Working Group. *Clinical and Translational Science* **13**, 116–124 (2020).
- 640 27. Buuren, S. V. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations
641 in R. *J. Stat. Soft.* **45**, (2011).
- 642 28. R Core Team. R: A language and environment for statistical computing. R Foundation for
643 Statistical Computing (2023).
- 644 29. Griffin, M. R. Epidemiology of Nonsteroidal Anti-inflammatory Drug–Associated Gastrointestinal
645 Injury. *The American Journal of Medicine* **104**, 23S-29S (1998).
- 646 30. Yadesa, T. M., Kitutu, F. E., Tamukong, R. & Alele, P. E. Predictors of hospital-acquired
647 adverse drug reactions: a cohort of Ugandan older adults. *BMC Geriatr* **22**, 359 (2022).
- 648 31. Sackeim, H. Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression Efficacy,
649 Side Effects, and Predictors of Outcome. *Neuropsychopharmacology* **25**, 713–728 (2001).
- 650 32. Uher, R. *et al.* Adverse reactions to antidepressants. *Br J Psychiatry* **195**, 202–210 (2009).
- 651 33. Rheker, J., Winkler, A., Doering, B. K. & Rief, W. Learning to experience side effects after
652 antidepressant intake – Results from a randomized, controlled, double-blind study.
653 *Psychopharmacology* **234**, 329–338 (2017).
- 654 34. Campos, A. I. *et al.* Impact of CYP2C19 metaboliser status on SSRI response: a retrospective
655 study of 9500 participants of the Australian Genetics of Depression Study. *The*
656 *Pharmacogenomics Journal* **22**, 130–135 (2022).
- 657 35. Del Tredici, A. L. *et al.* Frequency of CYP2D6 Alleles Including Structural Variants in the United
658 States. *Front. Pharmacol.* **9**, 305 (2018).
- 659 36. Fusar-Poli, L., Rutten, B. P. F., Van Os, J., Aguglia, E. & Guloksuz, S. Polygenic risk scores for
660 predicting outcomes and treatment response in psychiatry: hope or hype? *International Review*
661 *of Psychiatry* **34**, 663–675 (2022).
- 662 37. Pain, O. *et al.* Identifying the Common Genetic Basis of Antidepressant Response. *Biological*
663 *Psychiatry Global Open Science* **2**, 115–126 (2022).

- 664 38. Dudbridge, F. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genet* **9**,
665 e1003348 (2013).
- 666 39. Pillinger, T. *et al.* Antidepressant and antipsychotic side-effects and personalised prescribing: a
667 systematic review and digital tool development. *The Lancet Psychiatry* **10**, 860–876 (2023).
- 668 40. Reid, S. & Barbui, C. Long term treatment of depression with selective serotonin reuptake
669 inhibitors and newer antidepressants. *BMJ* **340**, c1468–c1468 (2010).
- 670 41. Edinoff, A. N. *et al.* Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative
671 Review. *Neurology International* **13**, 387–401 (2021).
- 672 42. Fornaro, M. *et al.* The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young
673 Adults: More Harm Than Benefits? *Front. Psychiatry* **10**, 294 (2019).
- 674 43. Coupland, C. *et al.* Antidepressant use and risk of adverse outcomes in older people:
675 population based cohort study. *BMJ* **343**, d4551–d4551 (2011).
- 676 44. Coupland, C. *et al.* Antidepressant use and risk of suicide and attempted suicide or self harm in
677 people aged 20 to 64: cohort study using a primary care database. *BMJ* **350**, h517–h517
678 (2015).
- 679 45. Smoller, J. W. The use of electronic health records for psychiatric phenotyping and genomics.
680 *American J of Med Genetics Pt B* **177**, 601–612 (2018).
- 681 46. Hunot, V. M., Horne, R., Leese, M. N. & Churchill, R. C. A Cohort Study of Adherence to
682 Antidepressants in Primary Care: The Influence of Antidepressant Concerns and Treatment
683 Preferences. *Prim. Care Companion J. Clin. Psychiatry* **09**, 91–99 (2007).
- 684

Side effect outcome




Prediction model





Side effect



Discontinuation



No Yes

a.**b.**






Table 1. Side effects and discontinuation at the prescription of the first and last year

| | Discontinuation | Side effect symptoms |
|---|------------------------|-----------------------------|
| Prescription at the first year (N (yes%)) | | |
| SSRI | 3947 (31.6) | 4286 (73.3) |
| Prescription at the last year (N (yes%)) | | |
| SSRI | 1770 (20.7) | 1986 (75.3) |
| SNRI | 640 (20.6) | 733 (83.5) |
| Tricyclic | 834 (37.2) | 959 (76.4) |